(BPT) - Prostate cancer is the second leading cause of death among men in the United States. In fact this year alone, an estimated 240,000 men will be diagnosed with prostate cancer and over 28,000 men are estimated to die from the disease. Recent advancements in screenings and detection for prostate cancer have resulted in more men being diagnosed at an earlier age.
These statistics solidify the need to create awareness with men and their families about the importance of early detection and innovative treatments available for this disease.
Prostate cancer survivor and advocate, Isadore Wayne of St. Louis, Missouri, was diagnosed with the disease at the age of 46 in 2002. After undergoing a series of treatments over several years for his own prostate cancer, including a radical prostatectomy and hormone therapy, Wayne’s cancer recurred and spread beyond the prostate. His oncologist then prescribed PROVENGE® (sipuleucel-T), a breakthrough treatment option designed to train the body’s immune cells to seek and attack prostate cancer cells.
FDA-approved for certain men with advanced prostate cancer, PROVENGE is the first and only immunotherapy approved in the U.S. that uses the body’s own immune system to fight prostate cancer. Each dose of PROVENGE is made specifically for each patient and consists of immune cells that have been activated to seek and attack prostate cancer cells. Isadore received his first infusion of PROVENGE in September 2011 and successfully completed treatment about one month later.
As a result, he now dedicates much of his time to educating his local community about the disease through a network of support groups. “Thanks to my friends, family and healthcare team, I’ve been able to fight my prostate cancer with the help of my own body,” says Wayne.
For men like Wayne who have been diagnosed with prostate cancer, awareness of recent research is vital to having an open discussion with a physician. Wendy Poage, president of the Prostate Conditions Education Council, encourages men with advanced prostate cancer to discuss their treatment options and advancements.
“Immunotherapy offers cancer patients a different approach to treatment,” says Poage. “With such favorable data on immunotherapies emerging, I’m certain the future of cancer treatment is here now.”
Awareness and education about prostate cancer are the best tools to fight against the disease. Encourage the men in your life to speak with a physician and become better educated about breakthrough treatment options like PROVENGE.
PROVENGE Indication and Safety Information
PROVENGE is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
PROVENGE can cause serious reactions including those resulting from the infusion of the drug, which occur within 1 day of infusion, and strokes. Severe infusion reactions can include chills, fever, fatigue, weakness, breathing problems, dizziness, headache, high blood pressure, muscle ache, nausea, and vomiting. The most common side effects reported with PROVENGE in clinical trials were chills, fatigue, fever, back pain, nausea, joint ache and headache. These are not all the possible side effects of PROVENGE treatment. For more information, please talk with your doctor.
For full prescribing information, visit http://www.provenge.com or call Dendreon on call at 1-877-336-3736.